FCN-589, a novel, potent and selective BTK inhibitor, targets BTK C481S for the treatment of B-cell malignancies

被引：0
|
作者：
Lin, Shu [1 ]
Tan, Haohan [1 ]
Liu, Qihong [1 ]
Wang, Yunling [1 ]
Liu, Bin [1 ]
Li, Zhifu [1 ]
Chen, Zhifang [1 ]
Wang, Xianlong [1 ]
Zhao, Xingdong [1 ]
Jiang, Lihua [1 ]
Wang, Xilei [1 ]
Cheng, Tao [1 ]
Zhou, Jiashu [2 ]
Wang, Weibo [1 ]
机构：
[1] Fochon Pharmaceut Ltd, Chongqing, Peoples R China
[2] Fochon Pharma Inc, San Leandro, CA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5438
引用
收藏
页数：2
相关论文
共 50 条
  • [1] AS-1763: a highly potent, noncovalent and next generation BTK inhibitor for the treatment of patients with B-cell malignancies having C481S mutation in BTK
    Kawahata, Wataru
    Asami, Tokiko
    Kiyoi, Takao
    Irie, Takayuki
    Kashimoto, Shigeki
    Furuichi, Hatsuo
    Sawa, Masaaki
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [2] HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies
    Wang, Linfang
    Liang, Junqing
    Gao, Zhihu
    Hu, Jia
    He, Weigang
    Yang, Xianwen
    Mao, Fangfang
    Zhang, Wei
    Yu, Ying
    Zhang, Qihang
    Yang, Na
    Zhang, Chun
    Wang, Jian
    Cai, Yu
    Li, Xiong
    Qing, Weiguo
    Dai, Guangxiu
    Ren, Yongxin
    Shi, Michael
    Su, Weiguo
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [3] PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
    Sun, Yonghui
    Zhao, Xingwang
    Ding, Ning
    Gao, Hongying
    Wu, Yue
    Yang, Yiqing
    Zhao, Meng
    Hwang, Jinseok
    Song, Yuqin
    Liu, Wanli
    Rao, Yu
    [J]. CELL RESEARCH, 2018, 28 (07) : 779 - 781
  • [4] PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
    Yonghui Sun
    Xingwang Zhao
    Ning Ding
    Hongying Gao
    Yue Wu
    Yiqing Yang
    Meng Zhao
    Jinseok Hwang
    Yuqin Song
    Wanli Liu
    Yu Rao
    [J]. Cell Research, 2018, 28 : 779 - 781
  • [5] REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK
    Guisot, Nicolas E. S.
    Best, Stuart A.
    Wright, Victoria
    Thomason, Andrew
    Woyach, Jennifer A.
    Mantel, Rose
    McClanahan, Fabienne
    Abet, Valentina
    Castagna, Diana
    Cousin, Peggy
    Emmerich, Juliette
    Ho, Kelvin
    Kelly, James Russell
    King-Tours, James
    Lyons, Kristina
    Muller, Melanie
    Refuerzo, Julienne
    Sargent, Louise
    Talab, Fatima
    Bingham, Matilda
    Phillips, Caroline
    Armer, Richard
    [J]. BLOOD, 2016, 128 (22)
  • [6] Development of novel Btk inhibitor, CB988 targering ibrutinib-resistant Btk C481S mutant
    Kawahata, Wataru
    Asami, Tokiko
    Irie, Takayuki
    Iwata, Yasuhiro
    Kiyoi, Takao
    Sawa, Masaaki
    [J]. CANCER RESEARCH, 2017, 77
  • [7] Development of REDX05194, a Novel, Potent and Selective Inhibitor of Bruton's Tyrosine Kinase (BTK) As a Potential Treatment for B-Cell Malignancies
    Walker, Victoria
    Guisot, Nicolas E. S.
    Best, Stuart
    Talab, Fatima
    Lucas, Catherine L.
    Refuerzo, Julienne
    Calder, Mathew
    Proctor, Lauren
    Muller, Melanie
    Ho, Kelvin
    Chappell, Rose
    Emmerich, Juliette
    Harmon, Shona
    Bingham, Matilda
    Campbell, Mary-Ann
    Armer, Richard
    [J]. BLOOD, 2015, 126 (23)
  • [8] M7583 Is a Highly Selective and Potent Second Generation BTK Inhibitor for Treatment of B-Cell Malignancies
    Goodstal, Samantha M.
    Ma, Jianguo
    Lin, Jing
    Crandall, Timothy
    Crowley, Lindsey
    Bender, Andrew
    Iadevaia, Riham
    Clark, Anderson
    [J]. BLOOD, 2017, 130
  • [9] CB1763, a highly selective, novel non-covalent BTK inhibitor, targeting ibrutinib-resistant BTK C481S mutant
    Asami, Tokiko
    Kawahata, Wataru
    Kashimoto, Shigeki
    Sawa, Masaaki
    [J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [10] ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
    Ghoshdastidar, Krishnarup
    Patel, Hoshang
    Bhayani, Hitesh
    Patel, Ankit
    Thakkar, Kinjal
    Patel, Dinesh
    Sharma, Manoranjan
    Singh, Jaideep
    Mohapatra, Jogeswar
    Chatterjee, Abhijit
    Patel, Dipam
    Bahekar, Rajesh
    Sharma, Rajiv
    Gupta, Lakshmikant
    Patel, Nirmal
    Giri, Poonam
    Srinivas, Nuggehally R.
    Jain, Mukul
    Bandyopadhyay, Debdutta
    Patel, Pankaj R.
    Desai, Ranjit C.
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (04):
12345